Maya Harary1,2,3, Vasileios K Kavouridis1,2, Matthew Torre2,4, Hasan A Zaidi1,2, Ugonma N Chukwueke2,5, David A Reardon1,2,5, Timothy R Smith1,2, J Bryan Iorgulescu1,2,4,6. 1. Computational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts. 2. Harvard Medical School, Boston, Massachusetts. 3. Department of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California. 4. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. 5. Center for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Center, Boston, Massachusetts. 6. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Abstract
BACKGROUND: Although surgery plays a crucial diagnostic role in World Health Organization (WHO) grade II 1p/19q-codeleted oligodendrogliomas, the role of maximal tumor surgical resection remains unclear, with early retrospective series limited by lack of molecular classification or appropriate control groups. METHODS: The characteristics, management, and overall survival (OS) of patients ≥20 years old presenting with histology-proven WHO grade II 1p/19q-codeleted oligodendrogliomas during 2010-2016 were evaluated using the National Cancer Database and validated using multi-institutional data. Patients were stratified by watchful waiting (biopsy only) versus surgical resection. OS was analyzed using Kaplan-Meier methods and risk-adjusted proportional hazards. RESULTS: Five hundred ninety adults met inclusion criteria, of whom 79.0% (n = 466) underwent surgical resection. Of patient and tumor characteristics, younger patients were more likely to be resected. Achieving gross total resection (GTR; n = 320) was significantly associated with smaller tumors, management at integrated network cancer programs (vs community cancer programs), and Medicare insurance (as compared with no, private, or Medicaid/other government insurance) and independent of other patient or tumor characteristics. In risk-adjusted analyses, GTR, but not subtotal resection (STR), demonstrated improved OS (vs biopsy only: hazard ratio 0.28, 95% CI: 0.09-0.85, P = 0.02). CONCLUSIONS: WHO grade II 1p/19q-codeleted oligodendrogliomas amenable to resection demonstrated improved OS with GTR, but not STR, compared with biopsy-only watchful waiting. The OS benefits of GTR were independent of age, tumor size, or tumor location. Medicare-insured and integrated network cancer program patients were significantly more likely to have GTR than other patients, suggesting that insurance status and care setting may play important roles in access to timely diagnosis or innovations that improve maximal resection.
BACKGROUND: Although surgery plays a crucial diagnostic role in World Health Organization (WHO) grade II 1p/19q-codeleted oligodendrogliomas, the role of maximal tumor surgical resection remains unclear, with early retrospective series limited by lack of molecular classification or appropriate control groups. METHODS: The characteristics, management, and overall survival (OS) of patients ≥20 years old presenting with histology-proven WHO grade II 1p/19q-codeleted oligodendrogliomas during 2010-2016 were evaluated using the National Cancer Database and validated using multi-institutional data. Patients were stratified by watchful waiting (biopsy only) versus surgical resection. OS was analyzed using Kaplan-Meier methods and risk-adjusted proportional hazards. RESULTS: Five hundred ninety adults met inclusion criteria, of whom 79.0% (n = 466) underwent surgical resection. Of patient and tumor characteristics, younger patients were more likely to be resected. Achieving gross total resection (GTR; n = 320) was significantly associated with smaller tumors, management at integrated network cancer programs (vs community cancer programs), and Medicare insurance (as compared with no, private, or Medicaid/other government insurance) and independent of other patient or tumor characteristics. In risk-adjusted analyses, GTR, but not subtotal resection (STR), demonstrated improved OS (vs biopsy only: hazard ratio 0.28, 95% CI: 0.09-0.85, P = 0.02). CONCLUSIONS: WHO grade II 1p/19q-codeleted oligodendrogliomas amenable to resection demonstrated improved OS with GTR, but not STR, compared with biopsy-only watchful waiting. The OS benefits of GTR were independent of age, tumor size, or tumor location. Medicare-insured and integrated network cancer program patients were significantly more likely to have GTR than other patients, suggesting that insurance status and care setting may play important roles in access to timely diagnosis or innovations that improve maximal resection.
Authors: Krzysztof Majchrzak; Wojciech Kaspera; Barbara Bobek-Billewicz; Anna Hebda; Gabriela Stasik-Pres; Henryk Majchrzak; Piotr Ładziński Journal: Clin Neurol Neurosurg Date: 2012-03-17 Impact factor: 1.876
Authors: Ashish H Shah; Karthik Madhavan; Deborah Heros; Daniel M S Raper; J Bryan Iorgulescu; Brian E Lally; Ricardo J Komotar Journal: Neurosurg Focus Date: 2011-12 Impact factor: 4.047
Authors: J Bryan Iorgulescu; Maya Harary; Cheryl K Zogg; Keith L Ligon; David A Reardon; F Stephen Hodi; Ayal A Aizer; Timothy R Smith Journal: Cancer Immunol Res Date: 2018-07-12 Impact factor: 11.151
Authors: Justin S Smith; Edward F Chang; Kathleen R Lamborn; Susan M Chang; Michael D Prados; Soonmee Cha; Tarik Tihan; Scott Vandenberg; Michael W McDermott; Mitchel S Berger Journal: J Clin Oncol Date: 2008-03-10 Impact factor: 44.544
Authors: A S Jakola; A J Skjulsvik; K S Myrmel; K Sjåvik; G Unsgård; S H Torp; K Aaberg; T Berg; H Y Dai; K Johnsen; R Kloster; O Solheim Journal: Ann Oncol Date: 2017-08-01 Impact factor: 32.976
Authors: Roland Roelz; David Strohmaier; Ramazan Jabbarli; Rainer Kraeutle; Karl Egger; Volker A Coenen; Astrid Weyerbrock; Peter C Reinacher Journal: Sci Rep Date: 2016-08-30 Impact factor: 4.379
Authors: Nayan Lamba; Malia McAvoy; Vasileios K Kavouridis; Timothy R Smith; Mehdi Touat; David A Reardon; J Bryan Iorgulescu Journal: Neurooncol Pract Date: 2022-01-14
Authors: Antonio Dono; Kristin Alfaro-Munoz; Yuanqing Yan; Carlos A Lopez-Garcia; Zaid Soomro; Garret Williford; Takeshi Takayasu; Lindsay Robell; Nazanin K Majd; John de Groot; Yoshua Esquenazi; Carlos Kamiya-Matsuoka; Leomar Y Ballester Journal: Neurosurgery Date: 2022-05-01 Impact factor: 5.315